Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Frontiers in Immunology · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective case series reporting complete radiographic remission in all five patients with metastatic solid tumors treated with doubly loaded autologous dendritic cell therapy, with responses sustained 6–28 months and no grade 3+ adverse events. Although the clinical outcomes are notable, the uncontrolled single-centre design, very small sample, and lack of comparator preclude conclusions about efficacy and the authors appropriately call for larger controlled studies.
Retrospective case series. Five adults (4 male, 1 female; median age 51 years, range 39–62) with metastatic solid tumors (prostate adenocarcinoma n=1, malignant melanoma n=2, triple-negative breast cancer n=1, urothelial carcinoma n=1) who had failed standard treatments (immune checkpoint inhibition, radiation, surgery, or e…. Intervention: Doubly loaded autologous dendritic cell therapy: three vaccines of approximately 5–7 million modified dendritic cells injected adjacent to the lymph node draining to the tumor site, administered over six weeks.. n = 5. Single site: Immunocine Cancer Center (location not specified in abstract)..
Five patients with metastatic solid tumors (prostate adenocarcinoma n=1, malignant melanoma n=2, triple-negative breast cancer n=1, urothelial carcinoma n=1) achieved complete radiographic remission All five patients had sustained responses ranging from 6 to 28 months, ongoing in all cases No grade 3 or higher adverse events observed
No grade 3 or higher adverse events observed
The complete responses in all five patients are clinically striking and warrant larger controlled investigation. However, a clinician should not alter practice based on this case series alone; the lack of a comparator, single-centre referral-based setting, and very small sample preclude generalization and may reflect selection bias or natural history variation.
Retrospective case series of five patients with durable complete responses to dendritic cell therapy, but uncontrolled, single-centre design with no comparator limits strength; observations merit larger trials but cannot establish efficacy or guide practice alone.
As stated by the source record.
Quoted from the source exactly as published.
The complete responses in all five patients are clinically striking and warrant larger controlled investigation. However, a clinician should not alter practice based on this case series alone; the lack of a comparator, single-centre referral-based setting, and very small sample preclude generalization and may reflect selection bias or natural history variation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Many patients with advanced solid tumors ultimately develop resistance to conventional therapies, with especially limited options for those experiencing rapid progression or poor performance status, highlighting the need for personalized immunotherapies capable of inducing durable responses. In this retrospective case series, we describe the clinical course and outcomes of five adults (4 male, 1 female; median age 51 years [range, 39–62]) with metastatic solid tumors who achieved complete and durable remission following doubly loaded autologous dendritic cell therapy after failure of standard treatments, such as immune checkpoint inhibition, radiation, surgery, or endocrine therapy. Five patients, including prostate adenocarcinoma (n=1), malignant melanoma (n=2), triple-negative breast cancer (n=1), and urothelial carcinoma (n=1), were treated between July 2022 and March 2025 at a single-site referral-based immunotherapy center (Immunocine Cancer Center). Over the course of six weeks, patients received three vaccines of approximately 5–7 million modified dendritic cells injected adjacent to the lymph node draining to the tumor site. Follow-up ranged from 6 to 28 months, where radiographic response, clinical performance status, and tumor and available clinical and biological biomarkers were assessed. All five patients achieved complete radiographic remission confirmed by PET/CT or histology, with sustained responses ranging from 6 to 28 months and ongoing in all cases, and no grade 3 or higher adverse events observed. These observations support further evaluation of doubly-loaded autologous dendritic cell therapy in larger, controlled studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.